Definium Therapeutics Us, Inc.
Clinical trials sponsored by Definium Therapeutics Us, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a modified MDMA ease autism symptoms? small trial begins Results expected Aug 2027 (estimated)
- Could a Psychedelic-Like pill beat depression? phase 3 trial underway Results expected Sep 2027 (estimated)
-
New anxiety pill shows promise in major trial
Symptom relief OngoingThis study tests an oral medication called MM120 against a placebo in 245 adults with generalized anxiety disorder. Participants take the drug or placebo for 12 weeks, and those who complete may join a 40-week follow-up where everyone gets the active drug. The goal is to see if M…
Phase 3 • Sponsor: Definium Therapeutics US, Inc. • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
New anxiety pill shows promise in Late-Stage trial
Symptom relief OngoingThis phase 3 study tests whether an oral medication called MM120 can reduce anxiety symptoms in adults with generalized anxiety disorder. About 214 participants will receive either MM120 or a placebo for 12 weeks, followed by a 40-week period where everyone can receive MM120. The…
Phase 3 • Sponsor: Definium Therapeutics US, Inc. • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
New depression pill shows promise in Late-Stage trial
Symptom relief OngoingThis study tests an oral medication called MM120 against a placebo in adults with major depressive disorder. The trial has two parts: a 12-week blinded phase followed by a 40-week open-label extension where everyone gets MM120. The main goal is to see if MM120 reduces depression …
Phase 3 • Sponsor: Definium Therapeutics US, Inc. • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC